Cohesys Company Profile

Background

Founded in 2018 and headquartered in Toronto, Canada, Cohesys is a medical device company dedicated to revolutionizing fracture repair solutions. The company's mission is to disrupt the traditional surgical repair industry, which heavily relies on invasive plates and screws, by introducing innovative, less invasive technologies. Cohesys's flagship product, BoneTape, exemplifies this mission by offering a resorbable fixation device designed to improve surgical outcomes and patient recovery.

Key Strategic Focus

Cohesys's strategic focus centers on developing and commercializing BoneTape, a novel resorbable bone fixation device. BoneTape is designed to realign and stabilize bone fragments, fixate fractures, bone grafts, and bone substitutes without the need for drilling into healthy bone. This approach aims to reduce surgical time, minimize trauma, and lower reoperation rates associated with traditional fracture repair methods. The company initially targets the craniomaxillofacial (CMF) fracture-surgery market, which comprises approximately 536,500 addressable procedures annually, representing a total procedural market of $8.8 billion, with $2.6 billion allocated to implantable devices like BoneTape.

Financials and Funding

Cohesys has secured significant funding to advance its product development and commercialization efforts. In July 2024, the company raised CA$500,000 in a seed funding round from the Ministry of Economic Development, Job Creation and Trade. Additionally, in January 2024, Cohesys was awarded $1.62 million by the Medical Technology Enterprise Consortium (MTEC) in collaboration with the U.S. Army Medical Research and Development Command (USAMRDC) to support the development and clinical validation of BoneTape. Furthermore, in June 2024, Alto Capital announced a Special Purpose Vehicle (SPV) fund to invest in Cohesys, providing accredited investors an opportunity to support the company's early-stage growth.

Pipeline Development

BoneTape is currently undergoing investigational testing and clinical validation. Cohesys is preparing an FDA application for human use of BoneTape through the 510(k) pathway, which typically does not require clinical data. However, to strengthen their application and support initial marketing and sales efforts, the company is conducting a clinical trial at Sunnybrook Hospital. This trial aims to provide robust data on BoneTape's safety and efficacy, positioning it for successful market entry.

Technological Platform and Innovation

Cohesys's innovation is anchored in its proprietary biomaterials platform, Coherence, which encompasses 36 transformative surgical materials designed to improve patient outcomes and reduce costs across multiple surgical indications. Coherence represents the first line of adherent materials with tunable properties and biodegradation times formulated for both soft and hard tissue applications. BoneTape, a product of this platform, is a resorbable, flexible fixation system composed entirely of resorbable materials. It is provided as a single piece that can be cut to shape during surgical procedures, eliminating the need for extensive instrument kits containing numerous plates, screws, and tools. This design simplifies surgeries, reduces distribution costs, and enhances workflow efficiency.

Leadership Team

Dr. Michael Floros: Founder and CEO of Cohesys.

Michael Tessier: Chief Operating Officer and Co-Founder.

Alexander Lausch: Senior Product Development Engineer and Co-Founder.

Janaina Bortolatto: Vice President of Clinical Operations.

Bryan Quan: Product Development Scientist.

Competitor Profile

Market Insights and Dynamics

The orthopedic surgery market is substantial, with the craniomaxillofacial (CMF) fracture-surgery segment alone representing an $8.8 billion market, of which $2.6 billion is allocated to implantable devices. Traditional fracture repair methods, such as metal plates and screws, have been in use since 1895, with limited innovation in materials and techniques. This longstanding reliance on invasive procedures presents an opportunity for disruptive technologies like BoneTape to offer less invasive, resorbable solutions that improve patient outcomes and reduce surgical complexities.

Competitor Analysis

Cohesys operates in a competitive landscape that includes established medical device companies specializing in orthopedic solutions. Key competitors include:

Stryker Corporation: A global leader in medical technologies, offering a wide range of orthopedic products, including plates and screws for fracture fixation.

DePuy Synthes (a subsidiary of Johnson & Johnson): Provides comprehensive orthopedic solutions, including traditional fixation devices for bone fractures.

Zimmer Biomet: Offers a broad portfolio of orthopedic products, including trauma fixation devices.

These competitors primarily focus on traditional, non-resorbable fixation devices, whereas Cohesys's BoneTape introduces a novel, resorbable alternative designed to reduce surgical invasiveness and improve patient recovery.

Strategic Collaborations and Partnerships

Cohesys has established significant partnerships to advance its mission:

Medical Technology Enterprise Consortium (MTEC): Awarded Cohesys $1.62 million in collaboration with the U.S. Army Medical Research and Development Command to support the development and clinical validation of BoneTape.

Alto Capital: Launched a Special Purpose Vehicle (SPV) fund to invest in Cohesys, providing accredited investors an opportunity to support the company's early-stage growth.

Operational Insights

Cohesys's strategic considerations include:

Market Positioning: By offering a resorbable, less invasive fixation device, Cohesys differentiates itself from competitors relying on traditional plates and screws.

Regulatory Strategy: Pursuing FDA approval through the 510(k) pathway, supported by clinical trials, to expedite market entry.

Manufacturing Efficiency: Designing BoneTape as a single piece that can be cut to shape during surgery reduces the need for extensive instrument kits, streamlining surgical procedures and reducing costs.

Strategic Opportunities and Future Directions

Cohesys is poised to capitalize on several strategic opportunities:

Market Expansion: Beyond the initial focus on craniomaxillofacial surgeries, BoneTape's adaptable design allows for potential applications in other orthopedic procedures, broadening the addressable market.

Technological Advancements: Continued innovation within the Coherence platform to develop additional resorbable surgical materials for various medical applications.

Global Reach: Leveraging partnerships and funding to expand operations and distribution channels internationally, addressing the global need for advanced fracture fixation solutions.